The Monoclonal Antibody PF-03446962 for HCC
Melanie B. Thomas, MD, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).
Clinical Pearls
Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibodyPF-03446962 in hepatocellular carcinoma (HCC).
- PF-03446962 is a fully human IgG2 monoclonal antibody against ALK-1.
- Higher tumor c-MET and serum BMP-9, and low serum TGF-β and VEGFR3 were observed in patients with disease control at 12 weeks compared with patients with progressive disease.
- This agent was mostly well tolerated rashes were observed in some patients.
- PF-03446962 will be looked at next compared with placebo in the second-line for HCC.
<<<
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
